KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NovoCure (NVCR) Retained Earnings (2016 - 2025)

NovoCure's Retained Earnings history spans 12 years, with the latest figure at -$3.4 million for Q4 2025.

  • For Q4 2025, Retained Earnings rose 37.44% year-over-year to -$3.4 million; the TTM value through Dec 2025 reached -$3.4 million, up 37.44%, while the annual FY2025 figure was -$3.4 million, 37.44% up from the prior year.
  • Retained Earnings for Q4 2025 was -$3.4 million at NovoCure, up from -$5.8 million in the prior quarter.
  • Across five years, Retained Earnings topped out at -$1.9 million in Q1 2021 and bottomed at -$1.2 billion in Q2 2025.
  • The 5-year median for Retained Earnings is -$672.7 million (2021), against an average of -$544.2 million.
  • The largest annual shift saw Retained Earnings soared 99.68% in 2022 before it crashed 42331.46% in 2023.
  • A 5-year view of Retained Earnings shows it stood at -$685.9 million in 2021, then skyrocketed by 99.65% to -$2.4 million in 2022, then plummeted by 40405.67% to -$985.5 million in 2023, then surged by 99.44% to -$5.5 million in 2024, then soared by 37.44% to -$3.4 million in 2025.
  • Per Business Quant, the three most recent readings for NVCR's Retained Earnings are -$3.4 million (Q4 2025), -$5.8 million (Q3 2025), and -$1.2 billion (Q2 2025).